Withdrawn × Leukemia × Lymphoid × Clear all
NCT00816413 2023-08-14

Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

University of Nebraska

Phase 1/2 Withdrawn
NCT00004114 2020-07-31

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
NCT00085449 2019-11-27

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Alliance for Clinical Trials in Oncology

Phase 1/2 Withdrawn
NCT00002956 2016-03-21

Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants

University of Alabama at Birmingham

Phase 1 Withdrawn
NCT00770419 2015-05-29

Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers

Rutgers, The State University of New Jersey

Withdrawn
NCT00024115 2015-04-28

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 1 Withdrawn
NCT00081055 2014-12-04

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Mesoblast, Ltd.

Phase 2 Withdrawn
NCT00458744 2014-08-08

Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment

Children's Oncology Group

Phase 1 Withdrawn
NCT01101412 2013-02-15

Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
NCT00301912 2012-10-02

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

University of California, San Francisco

Phase 2 Withdrawn
NCT00886496 2012-06-20

Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

Enzon Pharmaceuticals, Inc.

Phase 1 Withdrawn